Combination of chemotherapy with dual antagonists and radiotherapy in the treatment of neoplastic disease

The theoretical justification for combination chemotherapy and for the combination of radiation and chemotherapy in the treatment of neoplastic diseases is discussed, literature on the synthesis and biological activity of the ‘dual antagonist’ group of drugs is reviewed. Studies on the radiation‐potentiating effect of certain members of this group of drugs are reviewed, and prospects for therapeutic applications are discussed.

[1]  D. H. Murray.  Potentiation of cell growth inhibition by furanosides. , 1969, Journal of pharmaceutical sciences.

[2]  A. Munson,et al.  Studies on the chemistry, antitumor activity, and pharmacology of ethyl Di‐(2,2 ‐dimethyl)ethylenamido phosphate (AB‐163) , 1969, Journal of surgical oncology.

[3]  T. Bardos,et al.  SYNTHESIS OF POTENTIAL DUAL ANTAGONISTS. 3. RING-SUBSTITUTED ETHYL (BIS(1-AZIRIDINYL)PHOSPHINYL)CARBAMATES. , 1965, Journal of pharmaceutical sciences.

[4]  J. Webster,et al.  Combined use of AB‐132 (Meturedepa, Turloc) and X irradiation in the management of advanced bronchogenic carcinoma , 1964, Cancer.

[5]  T. Bardos.  Consideration of chemical reaction mechanisms in relationship to the biological action of "dual antagonists". , 1962, Biochemical pharmacology.

[6]  J. Sokal,et al.  Use of AB‐103 (a “dual antagonist”) in the treatment of bronchogenic carcinoma , 1961, Cancer.

[7]  A. Segaloff,et al.  Clinical Experience with AB‐100: Results of Therapy in 123 Patients , 1961, Southern medical journal.

[8]  A. Segaloff,et al.  ‘Dual Antagonists’; Alkyl N-(bis-(ethylenimido)phosphoro)-carbamates; a New Series of Anti-Tumour Agents , 1959, Nature.

[9]  A. Haddow.  FUTURE EXPERIMENTAL APPROACHES , 1958, Annals of the New York Academy of Sciences.

[10]  A. Gellhorn.  THE STATUS OF ALKYLATING AGENTS IN CLINICAL CANCER CHEMOTHERAPY , 1958, Annals of the New York Academy of Sciences.

[11]  G. Hitchings,et al.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. , 1954, The Journal of biological chemistry.

[12]  V. Potter.  Sequential Blocking of Metabolic Pathways in vivo ∗ , 1951, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  H. Skipper,et al.  Carbamates in the chemotherapy of leukemia. V. observation of a possible antileukemic synergism between urethane and methyl‐bis (β‐chloroethyl) amine , 1949 .

[14]  W. Shive,et al.  Prevention of phenylalanine synthesis by tyrosine. , 1947, The Journal of biological chemistry.